KRW98,300.00
0.71% day before yesterday
Korea, Jul 11, 08:11 am CET
ISIN
KR7326030004
Symbol
326030
Index
Sector
Industry

SK Biopharmaceuticals Stock price

KRW98,300.00
+5,100.00 5.47% 1M
-16,900.00 14.67% 6M
-12,800.00 11.52% YTD
+18,000.00 22.42% 1Y
+19,100.00 24.12% 3Y
-100,700.00 50.60% 5Y
-28,700.00 22.60% 10Y
-28,700.00 22.60% 20Y
Korea, Closing price Fri, Jul 11 2025
-700.00 0.71%
ISIN
KR7326030004
Symbol
326030
Index
Sector
Industry

Key metrics

Basic
Market capitalization
KRW7.8t
Enterprise Value
KRW7.6t
Net debt
positive
Cash
KRW268.7b
Shares outstanding
78.3m
Valuation (TTM | estimate)
P/E
30.6 | 51.3
P/S
13.4 | 10.7
EV/Sales
13.2 | 10.5
EV/FCF
88.3
P/B
13.7
Financial Health
Equity Ratio
52.7%
Return on Equity
44.1%
ROCE
16.6%
ROIC
56.0%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
KRW578.0b | KRW727.2b
EBITDA
KRW128.3b | KRW193.6b
EBIT
KRW111.7b | KRW158.1b
Net Income
KRW251.2b | KRW150.2b
Free Cash Flow
KRW86.2b
Growth (TTM | estimate)
Revenue
41.6% | 32.8%
EBITDA
992.7% | 70.2%
EBIT
2,544.5% | 64.2%
Net Income
1,520.7% | -37.6%
Free Cash Flow
387.9%
Margin (TTM | estimate)
Gross
92.8%
EBITDA
22.2% | 26.6%
EBIT
19.3%
Net
43.5% | 20.7%
Free Cash Flow
14.9%
More
EPS
KRW3,207.8
FCF per Share
KRW1,100.9
Short interest
-
Employees
-
Rev per Employee
-
Show more

Is SK Biopharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

SK Biopharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a SK Biopharmaceuticals forecast:

21x Buy
81%
4x Hold
15%
1x Sell
4%

Analyst Opinions

26 Analysts have issued a SK Biopharmaceuticals forecast:

Buy
81%
Hold
15%
Sell
4%

Financial data from SK Biopharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
577,999 577,999
42% 42%
100%
- Direct Costs 41,654 41,654
1% 1%
7%
536,345 536,345
47% 47%
93%
- Selling and Administrative Expenses 243,986 243,986
14% 14%
42%
- Research and Development Expense 164,095 164,095
17% 17%
28%
128,263 128,263
993% 993%
22%
- Depreciation and Amortization 16,548 16,548
1% 1%
3%
EBIT (Operating Income) EBIT 111,716 111,716
2,544% 2,544%
19%
Net Profit 251,211 251,211
1,521% 1,521%
43%

In millions KRW.

Don't miss a Thing! We will send you all news about SK Biopharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

SK Biopharmaceuticals Co., Ltd. engages in the research and development of new drugs and antibiotics. It mainly develops new drugs for central nervous system disorders, and brain tumors. The company was founded in 1993 and is headquartered in Seongnam-si, South Korea.

Head office South Korea
CEO Dong-Hoon Lee
Founded 1993
Website www.skbp.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today